The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.
 
Syed A. Hussain
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Pfizer; Pierre Fabre; Roche; Sotio
Research Funding - Boehringer Ingelheim; Janssen-Cilag; Pierre Fabre
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Janssen-Cilag; MSD Oncology; Pfizer; Pierre Fabre; Roche
 
Nobuaki Shimizu
No Relationships to Disclose
 
Wataru Obara
No Relationships to Disclose
 
Toshinari Yamasaki
No Relationships to Disclose
 
Satoru Takashima
Employment - Shionogi
Stock and Other Ownership Interests - Shionogi
 
Takahiro Hasegawa
Employment - Shionogi
Stock and Other Ownership Interests - Shionogi
 
Motofumi Iguchi
Employment - Shionogi
Stock and Other Ownership Interests - Shionogi
 
Kenji Igarashi
Employment - Shionogi
 
Osamu Ogawa
No Relationships to Disclose
 
Tomoaki Fujioka
No Relationships to Disclose